1MAES B,HADAYA K,DE MOOR B,et al.Severe diarrhea in renal transplant patients:results of the DIDACT study [ J ]. Am J Transplant, 2006,6 (6) : 1466-1472.
2WOILLARD J B, REROLLE J P, PICARD N, et al. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1 A8 2 variant allele [ J ]. Br J Clin Pharmacol, 2010,69 (6) :675-683.
3HELIR T,VAN GELDER T,BUDDE K,et al.Plasma co- ncentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients [ J ]. Am J Transplant,2007,7(7) :1822-1831.
4LE MEUR Y, BUCHLER M, THIERRY A, et al. Indivi- dualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation [ J ]. Am J Transplant, 2007,7 ( 11 ) : 2496 - 2503.
8DIAS V C, MADSEN K L, MULDER K E, et al. Oral administration of rapamyein and cyclosporine differentially alter intestinal function in rabbits [ J ]. Dig Dis Sci, 1998, (10) :2227-2236.
9MALINOWSKI M, MARTUS P, Lock J F, et al. Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function [ J ].Transpl Int, 2011, 24(2) :184-193.
10KAMAR N, FAURE P, DUPUIS E, et al. Villous atrophy induced by mycophenolate mofetil in renal-transplant patients [ J ] .Transpl Int, 2004,17 ( 8 ) : 463-467.
2LEE P,DIPERSIO D,JEROME R N,et al. Approaching andanalyzing a large literature on vancomycin monitoring andpharmacokinetics[J]. J Med Libr Assec,2007,95(4):374-379.
3NAKAYAMA H,ECHIZEN H,TANAKA M,et al. Reducedvancomycin clearance despite unchanged creatinine clearancein patients treared with vancomycin for longer than 4 weeks[J]. Ther Drug Monit,2008,30(1):103-107.
